[Clinical use of glycoprotein IIb/IIIa inhibitors].
Glycoprotein IIb/IIIa inhibitors are a new class of very powerful antiplatelet agents that act by inhibiting fibrinogen interplatelet bridges. Abciximab, tirofiban, lamifiban, and integrelin, all intravenous formulations, have been evaluated in phase II and phase III clinical trials. Although there seem to be relevant differences among drugs, their efficacy in treating acute ischemic syndromes and preventing acute complications of coronary angioplasty has been demonstrated. The major side effect has been an increase in bleeding complications. Future studies will be aimed at optimizing results and improving safety through more accurate assessment of optimal dosage and duration of infusion.
Simonetti
I
I
U.O. di Clinica Medica Generale e Cardiologia, Università degli Studi di Firenze.
Gallopin
M
M
Gensini
G F
GF
D000077284:Abciximab; D000800:Angioplasty, Balloon; D000911:Antibodies, Monoclonal / Q000009:adverse effects / Q000627:therapeutic use; D000077542:Eptifibatide; D005343:Fibrinolytic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D007140:Immunoglobulin Fab Fragments / Q000009:adverse effects / Q000627:therapeutic use; D007511:Ischemia / Q000188:drug therapy*; D010455:Peptides / Q000009:adverse effects / Q000627:therapeutic use; D010975:Platelet Aggregation Inhibitors / Q000009:adverse effects / Q000627:therapeutic use*; D019039:Platelet Glycoprotein GPIIb-IIIa Complex / Q000037:antagonists & inhibitors*; D000077466:Tirofiban; D014443:Tyrosine / Q000009:adverse effects / Q000031:analogs & derivatives / Q000627:therapeutic use
D000911:Antibodies, Monoclonal; D005343:Fibrinolytic Agents; D007140:Immunoglobulin Fab Fragments; D010455:Peptides; D010975:Platelet Aggregation Inhibitors; D019039:Platelet Glycoprotein GPIIb-IIIa Complex; D014443:Tyrosine; D000077466:Tirofiban; D000077542:Eptifibatide; D000077284:Abciximab
Impiego clinico degli inibitori della glicoproteina IIb/IIIa.